Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Fabry disease.
[fabry disease]
Fabry
disease
(
FD
)
is
an
X-
linked
disorder
caused
by
deficiency
of
the
enzyme
alpha-galactosidase
A
,
required
for
the
degradation
of
globotriaosylceramide
.
Accumulation
of
substrate
occurs
in
multiple
cell
types
resulting
in
a
multi-system
disorder
,
affecting
both
males
and
females
.
Clinical
features
include
neuropathic
pain
and
angiokeratoma
,
with
subsequent
development
of
proteinuria
,
renal
failure
,
left
ventricular
hypertrophy
,
arrhythmias
and
stroke
.
Beyond
palliative
therapies
for
organ
involvement
and
pain
control
,
enzyme
replacement
therapy
directed
at
the
underlying
metabolic
defect
became
available
in
2001
-
2003
.
Knowledge
of
the
pathophysiology
and
clinical
features
of
FD
is
vital
for
assessing
the
rationale
and
evidence
of
efficacy
of
therapies
for
FD
and
their
limitations
.
Whilst
ERT
improves
many
of
the
symptoms
of
FD
,
its
effect
on
the
natural
history
of
the
disorder
has
yet
to
be
fully
demonstrated
.
Improved
understanding
of
the
appropriate
use
of
adjunctive
therapies
and
the
development
of
new
treatment
strategies
,
including
pharmacologic
chaperone
therapy
and
gene
therapy
,
coupled
with
long
term
clinical
outcome
data
on
the
effects
of
ERT
are
all
key
components
of
optimising
treatment
for
FD
.
Diseases
Validation
Diseases presenting
"deficiency of the enzyme"
symptom
cystinuria
fabry disease
homocystinuria without methylmalonic aciduria
papillon-lefèvre syndrome
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom